Skip to main content
×
×
Home

Service innovations: a dedicated drug treatment service for dementia

  • Bart Sheehan (a1) and Karim Saad (a2)
Abstract
Aims and Method

To describe a targeted domiciliary drug treatment service for dementia and to establish clinical outcomes for its patients. All new referrals in a 6-month period were included. Data on clinical and demographic background, service performance and cognitive, functional and behavioural outcomes were recorded.

Results

Of 96 patients initiated on antidementia drugs, most had dementia of mild to moderate severity, and had heterogenous diagnoses. Significant improvements in cognition, behaviour and function were found.

Clinical Implications

A dedicated domiciliary drug treatment service for dementia achieved high levels of clinical activity and outcomes at least as good as clinical trials. This service model may be an attractive choice.

  • View HTML
    • Send article to Kindle

      To send this article to your Kindle, first ensure no-reply@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about sending to your Kindle. Find out more about sending to your Kindle.

      Note you can select to send to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be sent to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

      Find out more about the Kindle Personal Document Service.

      Service innovations: a dedicated drug treatment service for dementia
      Available formats
      ×
      Send article to Dropbox

      To send this article to your Dropbox account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your <service> account. Find out more about sending content to Dropbox.

      Service innovations: a dedicated drug treatment service for dementia
      Available formats
      ×
      Send article to Google Drive

      To send this article to your Google Drive account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your <service> account. Find out more about sending content to Google Drive.

      Service innovations: a dedicated drug treatment service for dementia
      Available formats
      ×
Copyright
This is an Open Access article, distributed under the terms of the Creative Commons Attribution (CC-BY) license (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted re-use, distribution, and reproduction in any medium, provided the original work is properly cited.
References
Hide All
AD2000 Collaborative Group (2004) Long-term donepezil treatment in 565 patients with Alzheimer's disease (AD2000): randomised double-blind trial. Lancet, 363, 21052115.
Anderson, D. & Aquilina, C. (2002) Domiciliary clinics: I. effects on non-attendance. International Journal of Geriatric Psychiatry, 17, 941944.
Bucks, R., Ashworth, D., Wilcock, G., et al (1996) Assessment of activities of daily living in dementia: development of the Bristol Activities of Daily Living scale. Age and Ageing, 25, 113120.
Department of Health (2001) National Service Framework for Older People. London: Department of Health.
Erkinjutti, T., Kurz, A., Gauthier, S., et al (2002) Efficacy of galantamine in probable vascular dementia and Alzheimer's disease combined with cerebrovascular disease: a randomised trial. Lancet, 359, 12831290.
Farlow, M., Anand, R., Messina, J., et al (2000) A 52-week study of the efficacy of rivastigmine inpatients with mild to moderate Alzheimer's disease. European Neurology, 44, 236241.
Folstein, M., Folstein, S. & McHugh, P. (1975) ‘Mini-mental state’: a practical method for grading the cognitive state of patients for the clinician. Journal of Psychiatric Research, 12, 189198.
Mathuranath, P., Nestor, P., Berrios, G., et al (2000) A brief cognitive test battery to differentiate Alzheimer's disease and frontotemporal dementia. Neurology, 55, 16131620.
Matthews, H., Korbey, J., Wilkinson, D., et al (2000) Donepezil in Alzheimer's disease: eighteen month results from Southampton memory clinic. International Journal of Geriatric Psychiatry, 15, 713720.
McKeith, I., Del Ser, T., Spano, P., et al (2000) Efficacy of rivastigmine in dementia with Lewy bodies: a randomised double-blind, placebo controlled international study. Lancet, 356, 20312036.
National Institute of Clinical Excellence (2001) Guidance on the Use of Donepezil, Rivastigmine and Galantamine for the Treatment of Alzheimer's Disease. London: NICE.
Reisberg, B., Borenstein, J., Salob, S., et al (1987) Behavioral symptoms in Alzheimer's disease: phenomenology and treatment. Journal of Clinical Psychiatry, 48, 915.
Reisberg, B., Doody, R., Stoffler, A., et al (2003) Memantine in moderate-to-severe Alzheimer's disease. New England Journal of Medicine, 348, 13331341.
Rogers, S., Doody, R., Mohs, R., et al (1998) Donepezil improves cognition and global function in Alzheimer disease. Archives of Internal Medicine, 158, 10211031.
Wilcock, G., Lilienfeld, S., Gaens, E. & THE GALANTAMINE-INTERNATIONAL-1 STUDY GROUP (2000) Efficacy and safety of galantamine in patients with mild to moderate Alzheimer's disease: multicentre randomised controlled trial. BMJ, 321, 14451449.
Recommend this journal

Email your librarian or administrator to recommend adding this journal to your organisation's collection.

BJPsych Bulletin
  • ISSN: 0955-6036
  • EISSN: 1472-1473
  • URL: /core/journals/bjpsych-bulletin
Please enter your name
Please enter a valid email address
Who would you like to send this to? *
×

Metrics

Full text views

Total number of HTML views: 0
Total number of PDF views: 1 *
Loading metrics...

Abstract views

Total abstract views: 15 *
Loading metrics...

* Views captured on Cambridge Core between 2nd January 2018 - 20th July 2018. This data will be updated every 24 hours.

Service innovations: a dedicated drug treatment service for dementia

  • Bart Sheehan (a1) and Karim Saad (a2)
Submit a response

eLetters

No eLetters have been published for this article.

×

Reply to: Submit a response


Your details


Conflicting interests

Do you have any conflicting interests? *